Stock ALPM.Y ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Astellas Pharma Inc. OTC Markets

Equities

ALPM.Y

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 01:29:59 06/06/2024 am IST 		5-day change 1st Jan Change
10.23 USD +1.69% Intraday chart for Astellas Pharma Inc. +6.01% -14.03%
03/06 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
31/05 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 31,86,231 31,05,395 31,61,421 35,19,738 33,81,409 28,58,917 - -
Enterprise Value (EV) 1 28,75,157 27,77,545 28,29,733 32,03,752 30,04,569 26,11,086 33,38,227 32,48,261
P/E ratio 14.4 x 16 x 26.2 x 28.5 x 34.7 x 173 x 34.9 x 18.2 x
Yield 2.29% 2.39% 2.47% 2.62% 3.19% 4.26% 4.7% 5%
Capitalization / Revenue 2.44 x 2.39 x 2.53 x 2.72 x 2.23 x 1.84 x 1.71 x 1.63 x
EV / Revenue 2.2 x 2.14 x 2.26 x 2.47 x 1.98 x 1.63 x 1.99 x 1.85 x
EV / EBITDA 9.35 x 8.95 x 13.6 x 13.6 x 12.6 x 14.2 x 11.5 x 8.45 x
EV / FCF 12.3 x -16.6 x 10.3 x 14.1 x 10.3 x -3.88 x 13 x 12.9 x
FCF Yield 8.12% -6.04% 9.73% 7.08% 9.7% -25.8% 7.71% 7.76%
Price to Book 2.49 x 2.41 x 2.28 x 2.39 x 2.24 x 1.85 x 1.89 x 1.87 x
Nbr of stocks (in thousands) 19,21,152 18,58,405 18,57,474 18,41,831 17,95,756 17,92,986 - -
Reference price 2 1,658 1,671 1,702 1,911 1,883 1,594 1,594 1,594
Announcement Date 25/04/19 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 13,06,348 13,00,843 12,49,528 12,96,163 15,18,619 16,03,672 16,75,525 17,57,985
EBITDA 1 3,07,370 3,10,387 2,08,703 2,35,370 2,38,767 1,83,358 2,91,406 3,84,319
EBIT 1 2,43,912 2,43,991 1,36,051 1,55,686 1,33,029 25,518 1,28,544 2,19,113
Operating Margin 18.67% 18.76% 10.89% 12.01% 8.76% 1.59% 7.67% 12.46%
Earnings before Tax (EBT) 1 2,48,967 2,45,350 1,45,324 1,56,886 1,32,361 24,969 1,10,854 2,08,104
Net income 1 2,22,265 1,95,411 1,20,589 1,24,086 98,714 17,045 81,864 1,57,227
Net margin 17.01% 15.02% 9.65% 9.57% 6.5% 1.06% 4.89% 8.94%
EPS 2 115.0 104.2 64.93 67.08 54.24 9.510 45.63 87.80
Free Cash Flow 1 2,33,440 -1,67,795 2,75,459 2,26,705 2,91,326 -6,73,327 2,57,448 2,52,148
FCF margin 17.87% -12.9% 22.05% 17.49% 19.18% -41.99% 15.37% 14.34%
FCF Conversion (EBITDA) 75.95% - 131.99% 96.32% 122.01% - 88.35% 65.61%
FCF Conversion (Net income) 105.03% - 228.43% 182.7% 295.12% - 314.48% 160.37%
Dividend per Share 2 38.00 40.00 42.00 50.00 60.00 70.00 74.93 79.67
Announcement Date 25/04/19 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2020 S2 2021 S1 2021 S2 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2025 S2 2026 S1 2026 S2
Net sales 1 6,50,470 - 6,15,480 - 3,25,523 6,51,666 3,40,627 3,03,870 - 3,81,791 3,80,394 7,62,185 4,02,180 3,54,254 3,74,990 3,92,148 7,67,138 4,21,932 4,14,602 - 4,11,043 4,26,825 8,00,647 4,54,342 3,92,474 - - -
EBITDA 1 - - - - - - - - - - - - - - - - - 70,087 42 - 89,100 81,600 - 1,13,400 9,300 - - -
EBIT 1 1,62,196 - 86,872 - 54,079 90,169 79,202 -13,685 - 33,147 86,744 1,19,891 61,388 -48,250 45,794 5,222 51,016 23,103 -48,601 - 36,354 44,147 83,888 62,996 -32,022 - - -
Operating Margin 24.94% - 14.11% - 16.61% 13.84% 23.25% -4.5% - 8.68% 22.8% 15.73% 15.26% -13.62% 12.21% 1.33% 6.65% 5.48% -11.72% - 8.84% 10.34% 10.48% 13.87% -8.16% - - -
Earnings before Tax (EBT) 1 1,61,584 - 89,091 - 53,255 89,085 78,317 -10,516 - 31,679 88,801 1,20,480 59,758 -47,877 46,850 5,328 52,178 21,452 -48,661 - 36,318 44,696 80,888 63,561 -29,096 - - -
Net income 1 1,28,527 - 72,838 - 40,922 71,609 60,886 -8,409 - 24,812 71,622 96,434 48,405 -46,125 33,129 -1,459 31,670 18,653 -33,278 - 27,999 34,678 59,857 49,383 -22,479 - - -
Net margin 19.76% - 11.83% - 12.57% 10.99% 17.87% -2.77% - 6.5% 18.83% 12.65% 12.04% -13.02% 8.83% -0.37% 4.13% 4.42% -8.03% - 6.81% 8.12% 7.48% 10.87% -5.73% - - -
EPS 2 68.16 - 39.21 - 22.09 38.65 32.86 -4.430 - 13.59 39.28 52.87 26.56 -25.19 18.46 -0.8000 17.66 10.40 -18.55 - 9.885 14.12 33.40 20.20 -19.31 - - -
Dividend per Share 2 20.00 20.00 21.00 21.00 - 25.00 - - 25.00 - - 30.00 - - - 35.00 35.00 - 35.00 35.00 - - 37.00 - - 37.00 39.00 39.00
Announcement Date 31/10/19 14/05/20 30/10/20 27/04/21 29/10/21 29/10/21 02/02/22 27/04/22 27/04/22 01/08/22 31/10/22 31/10/22 06/02/23 27/04/23 01/08/23 01/11/23 01/11/23 05/02/24 25/04/24 25/04/24 - - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - 5,03,449 4,79,310 3,89,344
Net Cash position 1 3,11,074 3,27,850 3,31,688 3,15,986 3,76,840 3,35,687 - -
Leverage (Debt/EBITDA) - - - - - 1.9 x 1.645 x 1.013 x
Free Cash Flow 1 2,33,440 -1,67,795 2,75,459 2,26,705 2,91,326 -6,73,327 2,57,448 2,52,148
ROE (net income / shareholders' equity) 17.6% 15.3% 9% 8.7% 6.7% 1.1% 6.48% 10.7%
ROA (Net income/ Total Assets) 13.3% 11.6% 6.33% 6.81% 5.53% 3.28% 4.33% 7.07%
Assets 1 16,76,516 16,78,858 19,05,121 18,21,523 17,85,770 5,19,665 18,91,831 22,24,962
Book Value Per Share 2 667.0 694.0 748.0 799.0 839.0 890.0 842.0 855.0
Cash Flow per Share 2 148.0 140.0 104.0 110.0 112.0 97.50 175.0 182.0
Capex 1 25,190 41,267 31,384 30,739 36,441 38,056 55,000 58,060
Capex / Sales 1.93% 3.17% 2.51% 2.37% 2.4% 2.37% 3.28% 3.3%
Announcement Date 25/04/19 14/05/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,594 JPY
Average target price
1,966 JPY
Spread / Average Target
+23.28%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.69% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.87% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.74% 326B
ABBVIE INC. Stock AbbVie Inc.
+6.76% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 246B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 213B
NOVARTIS AG Stock Novartis AG
+11.35% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.64% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPM.Y Stock
  5. Financials Astellas Pharma Inc.